Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Supplementation with cholecalciferol 1000 IU/day during pregnancy is associated with greater offspring bone mineral density during childhood.

Patients with cystic fibrosis (CF) experience significant bone mineral density (BMD) loss at a younger age than those without the disease, with greater decline observed among individuals with ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Depression and fluoxetine negatively impact bone mineral density and implant osseointegration independently suggests a study ...

Lung transplant patients should undergo annual bone health screenings using dual-energy X-ray absorptiometry for the first ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...